- Home
- ONTO vs ABVX Comparison
ONTO vs ABVX Comparison
Compare ONTO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTO
- ABVX
- Stock Information
- Founded
- ONTO 1940
- ABVX 2013
- Country
- ONTO United States
- ABVX France
- Employees
- ONTO N/A
- ABVX N/A
- Industry
- ONTO Industrial Machinery/Components
- ABVX
- Sector
- ONTO Industrials
- ABVX
- Exchange
- ONTO Nasdaq
- ABVX Nasdaq
- Market Cap
- ONTO 4.9B
- ABVX 5.3B
- IPO Year
- ONTO N/A
- ABVX N/A
- Fundamental
- Price
- ONTO $110.93
- ABVX $84.01
- Analyst Decision
- ONTO Strong Buy
- ABVX Strong Buy
- Analyst Count
- ONTO 7
- ABVX 8
- Target Price
- ONTO $137.86
- ABVX $90.63
- AVG Volume (30 Days)
- ONTO 983.5K
- ABVX 1.2M
- Earning Date
- ONTO 10-30-2025
- ABVX 08-11-2025
- Dividend Yield
- ONTO N/A
- ABVX N/A
- EPS Growth
- ONTO 20.58
- ABVX N/A
- EPS
- ONTO 4.04
- ABVX N/A
- Revenue
- ONTO $1,036,353,000.00
- ABVX $7,073,400.00
- Revenue This Year
- ONTO $3.11
- ABVX $25.23
- Revenue Next Year
- ONTO $11.98
- ABVX N/A
- P/E Ratio
- ONTO $27.54
- ABVX N/A
- Revenue Growth
- ONTO 15.51
- ABVX N/A
- 52 Week Low
- ONTO $85.88
- ABVX $4.77
- 52 Week High
- ONTO $228.42
- ABVX $92.91
- Technical
- Relative Strength Index (RSI)
- ONTO 62.05
- ABVX 67.94
- Support Level
- ONTO $102.91
- ABVX $82.72
- Resistance Level
- ONTO $105.35
- ABVX $91.30
- Average True Range (ATR)
- ONTO 2.73
- ABVX 3.62
- MACD
- ONTO 0.12
- ABVX -1.13
- Stochastic Oscillator
- ONTO 85.31
- ABVX 47.89
About ONTO Onto Innovation Inc.
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.